Main Line

Following the Recent Label Expansion, Biohaven’s Nurtec ODT Has Come Out Strong in the Migraine Prevention Market, According to Spherix Global Insights

EXTON, Pa., Sept. 9, 2021 /PRNewswire/ — In May 2021, the FDA approved the label expansion of Biohaven’s Nurtec ODT for the preventive treatment of episodic migraine, making the gepant the first and ...
The Times Herald

Biohaven’s Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly’s Emgality, According to Spherix ...

EXTON, Pa., Sept. 23, 2021 /PRNewswire/ — Just weeks after the FDA approval of Nurtec ODT’s label expansion for the preventive treatment of episodic migraine, Eli Lilly announced initiation of a ...
Nasdaq

Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the ...
Business Insider

Biohaven's NURTEC™ ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults

NEW HAVEN, Conn., March 12, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company (NYSE: BHVN) today announced that NURTEC™ ODT (rimegepant) is now available by prescription in U.S. pharmacies.
KRQE Blogs

Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific ...

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data Late-breaking submissions showcase new data ...
BioWorld

Biohaven's Nurtec becomes first oral CGRP for migraine prevention

The second oral CGRP antagonist to win FDA approval for acute migraine care is now the first to add preventive treatment to its label, marking a valuable win for Biohaven Pharmaceutical Holding Co.